Skyhawk Therapeutics expands its global pivotal Huntington disease trial to the United States, Canada and the United Kingdom, accelerating the path toward potential approval
Executive summary: Skyhawk Therapeutics announced the expansion of its global pivotal Phase 1/2 FALCON-HD trial of SKY-0515 for Huntington disease to include sites in the United States, Canada and the United Kingdom, completing recruitment of over 175 patients across more than ten countries and twenty locations. The wider geographic footprint enhances data diversity and may accelerate regulatory review, offering a much‑needed disease‑modifying option for Huntington disease, a condition with limited approved therapies.
Who is involved: Skyhawk Therapeutics (sponsor), clinical trial investigators in the US, Canada, UK and other countries, enrolled Huntington disease patients, and regulators such as the FDA, Health Canada and the MHRA.
Likely next: Interim analysis of the FALCON‑HD data is expected later in 2026, followed by top‑line results in early 2027 and potential discussions with regulators about advancing to a pivotal Phase 3 program.
The announcement confirms that patient recruitment for the Phase 1/2 FALCON-HD study of SKY-0515 is complete, with over 175 participants enrolled across more than ten countries and twenty sites. By adding locations in the US, Canada and UK, the trial gains broader geographic diversity, which regulators often view favorably when assessing safety and efficacy data. This progression signal advances a therapeutic area that currently lacks disease‑modifying treatments and may shorten the timeline for future regulatory submissions.
Timeline
- — Skyhawk Therapeutics gibt die Ausweitung seiner globalen zulassungsrelevanten klinischen Studie „FALCON-HD" für SKY-0515 zur Behandlung der Huntington-Krankheit auf die Vereinigten Staaten, Kanada und das Vereinigte Königreich bekannt (PR Newswire)
- — Skyhawk Therapeutics annonce l'extension aux États-Unis, au Canada et au Royaume-Uni de son essai clinique pivot mondial FALCON-HD portant sur le médicament SKY-0515 dans le traitement de la maladie de Huntington (PR Newswire)
- — Skyhawk Therapeutics: expansión de su ensayo clínico FALCON-HD para SKY-0515 en la enfermedad de Huntington (PR Newswire)
Analysis — what this means
Sectors affected
- Huntington disease therapeutics
- Neurodegenerative disease clinical trials
- Biotechnology
Regulatory implications
- FDA may accept multinational trial data from the newly added US, Canada and UK sites for a future New Drug Application
- Health Canada and MHRA will review the expanded safety database as part of their national review processes
- Positive efficacy signals could support requests for accelerated pathways such as FDA Breakthrough Therapy designation
Historical parallels
- Phase III trial of tominersen for Huntington disease was halted for futility in 2021
- Pridopidine (ACR16) was evaluated in the HORIZON study completed in 2020 with mixed efficacy results
- The first antisense oligonucleotide (IONIS‑HTTRx) trial demonstrated target engagement in Huntington disease patients in 2017
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped